The present invention provides crystalline escitalopram hydrobromide
((S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenz-
o-furan carbonitrile hydrobromide), and a novel crystalline form of
escitalopram hydrobromide referred to herein as Form I. Form I is stable,
water soluble, and not hygroscopic at a relative humidity less than 70%.
